首页 › 基金 › WASATCH ADVISORS LP › HALO

WASATCH ADVISORS LP 对 HALO 的持仓历史

HALOZYME THERAPEUTICS INC · 医疗保健

WASATCH ADVISORS LP 在 Q3 2026 的 13F 申报中披露持有 HALO(HALOZYME THERAPEUTICS INC)1,049,647 股,市值约 US$115.9M,约占其申报组合的 0.86%,在其申报持仓中市值排名第 44 位。 WASATCH ADVISORS LP 于 Q3 2026 首次申报该持仓。

最新持仓 (Q3 2026)1.05M 股
申报持仓市值$115.88M
组合权重0.86%
首次申报Q3 2026
最近变动新进
更新于2026-10-15

最后更新: 2026-10-15 · 来源: SEC EDGAR Form 13F-HR

WASATCH ADVISORS LP 对 HALO 的持仓演变

WASATCH ADVISORS LP 于 Q3 2026 首次披露 HALO 持仓:1,049,647 股(约 US$115.9M)。

逐季持仓明细

季度股数金额变化
Q3 2026 1.05M $115.88M 新进

关于 HALO 与 13F 数据

HALO(HALOZYME THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 42 只申报持有 HALO,申报仓位最大的包括:CONGRESS ASSET MANAGEMENT CO (US$251.9M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$196.5M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 HALO 的基金

查看 HALO 的全部基金持有人 →

常见问题

How long has WASATCH ADVISORS LP held HALO?

WASATCH ADVISORS LP has disclosed HALO holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is WASATCH ADVISORS LP's current position in HALO?

As of Q3 2026, WASATCH ADVISORS LP holds 1.05M shares of HALO (HALOZYME THERAPEUTICS INC), valued at $115.88M, representing 0.86% of its reported portfolio and ranking #44.

Has WASATCH ADVISORS LP been buying or selling HALO?

In the latest 13F filing (Q3 2026), WASATCH ADVISORS LP newly opened its position in HALO.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, SNYDER CAPITAL MANAGEMENT L P, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.